GO
Loading...

Drugs

More

  • Immunotherapies hit ASCO     Thursday, 29 May 2014 | 3:35 PM ET

    This year's biggest cancer conference begins tomorrow. CNBC's Meg Tirrell reports why immunotherapy drugs will be a key theme with drug makers at ASCO.

  • GSK invites private equity bid for drugs: Sources Thursday, 29 May 2014 | 12:34 PM ET
    A GlaxoSmithKline Plc logo sits on a sign outside the company's headquarters in London, U.K.

    GSK has invited private equity firms to consider making offers for a range of its older drugs, three people with direct knowledge of the matter said.

  • NEW YORK, May 29- Three Connecticut doctors billed Medicare for nearly 24,000 drug tests in 2012- on just 145 patients. Despite the extraordinary number, Medicare administrators paid the doctors a total of $1.4 million, according to a Reuters analysis of government payments to health providers.

  • Ataluren drives PTC Therapeutics     Friday, 23 May 2014 | 10:25 AM ET

    CNBC's Meg Tirrell reports shares of PTC Therapeutics are surging on a recommendation of the drug "Ataluren" designed to treat Duchenne muscular dystrophy which could be a billion dollar drug.

  • LONDON, May 20- Smokers trying to quit are 60 percent more likely to report success if they switch to e-cigarettes than if they use nicotine products like patches or gum, or just willpower, scientists said on Wednesday.

  • Pfizer: A deal to dodge the tax man in America Tuesday, 13 May 2014 | 2:28 AM ET

    Pfizer's pursuit of AstraZeneca raises a huge public policy red flag, writes Andrew Ross Sorkin in the New York Times.

  • Colombian Finance Minister Mauricio Cárdenas Santamaria says resolving the country's drugs issue will help the country post stronger growth.

  • Teva's abuse-resistant painkiller succeeds in study Wednesday, 30 Apr 2014 | 8:33 AM ET

    April 30- Israel's Teva Pharmaceutical Industries Ltd said its experimental abuse-resistant pain drug significantly reduced patients' chronic low back pain in a late-stage trial. The drug is a twice-daily formulation of hydrocodone, which belongs to a powerful class of painkillers known as opioids that are also frequently abused.

  • Biogen barreling down on Alzheimer's     Wednesday, 23 Apr 2014 | 3:33 PM ET

    CNBC's Meg Tirrell speaks with George Scangos, Biogen Idec CEO, about the drug maker's fight against MS and Alzheimer's. Scangos also comments on Valeant's bid for Alllergan.

  • Investor pressure pushing drugmaker M&A deals Wednesday, 23 Apr 2014 | 6:11 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.

  • On a high: Hemp to boost US economy?     Wednesday, 16 Apr 2014 | 11:40 AM ET

    The hemp industry could become one of the U.S.'s biggest now its industrial use had been legalized, says Doug Fine, author of "Hemp Bound".

  • District Court judge on Tuesday stopped Massachusetts from implementing a ban on the sale of Zogenix Inc's prescription painkiller Zohydro, saying federal law superseded the state's action.

  • District Court judge on Tuesday stopped Massachusetts from implementing a ban on the sale of Zogenix Inc's prescription painkiller Zohydro, saying federal law superceded the state's action.

  • Luis Videgaray, finance minister of Mexico, says the U.S. must "share responsibility" for tackling drug cartels.

  • WASHINGTON, April 10- The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

  • Pfizer CEO worries about ACA coverage     Thursday, 10 Apr 2014 | 11:43 AM ET

    Ian Read, Pfizer CEO, discusses the pricing and affordability of drugs in the U.S. Read also weighs in on insurance coverage under the Affordable Care Act.

  • Diversifying your pharma portfolio     Monday, 7 Apr 2014 | 1:07 PM ET

    Mallinckrodt is buying drug maker Questcor for $5.6 billion. Barbara Ryan, FTI Consulting managing director, discusses consolidation in pharmaceuticals and shares what stocks she likes in the space.

  • Why this $84,000 drug costs just $900 abroad Saturday, 29 Mar 2014 | 2:29 PM ET

    Why do some drugs, like Gilead's Sovaldi, cost more in the U.S. than in other countries. Shelia Dharmarajian reports for "Nightly Business Report."

  • CALGARY, Alberta, March 27- Canada's largest oil producer, Suncor Energy Inc, said on Thursday it will appeal a legal decision preventing the company from carrying out random drug and alcohol tests on workers at its northern Alberta oil sands sites.

  • 'Eye-opening' new report about statin eligibility Wednesday, 19 Mar 2014 | 5:06 PM ET
    Lipitor tablets

    Almost half of Americans ages 40 to 75 qualify to consider cholesterol-lowering statin drugs under new heart disease prevention guidelines.